Recombinant Cynomolgus B7-1/CD80 Protein (Fc Tag) | PKSQ050018

Recombinant Cynomolgus B7-1/CD80 Protein (Fc Tag) | PKSQ050018 | Gentaur US, UK & Europe Disrtribition

Synonyms: T-lymphocyte activation antigen CD80; Activation B7-1 antigen; B7; CD80

Active Protein: N/A

Activity: Recombinant Cynomolgus CD80 is produced by our Mammalian expression system and the target gene encoding Val35-Asn242 is expressed with a Fc tag at the C-terminus.

Protein Construction: Recombinant Cynomolgus CD80 is produced by our Mammalian expression system and the target gene encoding Val35-Asn242 is expressed with a Fc tag at the C-terminus.

Fusion Tag: C-Fc

Species: Cynomolgus

Expressed Host: Human Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per μg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 51 kDa

Formulation: Lyophilized from a 0.2 μm filtered solution of 50 mM Tris, 100 mM Glycine, pH 7.5.

Reconstitution: Please refer to the printed manual for detailed information.

Background: Cynomologous Cluster of Differentiation 80, also called B7-1, is a member of cell surface immunoglobulin superfamily.It is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells.CD80 plays key, yet distinct roles in the activation of T cells. B7-1/CD80 and B7-2/CD86, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T- and B- cell responses. CD80 is mostly expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Research Area: N/A